Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

Immune-related Adverse EventDiarrheaAdvanced MelanomaAdvanced Rectal Carcinoma

Interventions

DRUG

Mesalamine

Mesalamine, also known as 5-aminosalicylic acid (5-ASA)

Trial Locations (1)

RECRUITING

Cross Cancer Institute, Edmonton

All Listed Sponsors

lead

AHS Cancer Control Alberta

OTHER